Cancer treatment has evolved significantly, with a growing recognition that high-quality care extends beyond treating the disease alone. Multiple guidelines emphasize the need for comprehensive person ...

Real-world use of accelerated approval oncology drugs subsequently withdrawn in the United States. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2 once on day 1, then 2g/m 2 once on days 2-7] × six) to patients showing a ...

In the discovery cohort, read mapping to intratumoral Escherichia was associated with significantly longer OS (16 v 11 months; hazard ratio, 0.73 [95% CI, 0.59 to 0.92]; P = .0065) in patients treated ...

The therapeutic potential of PD-1/PD-L1 inhibition has led to the development of multiple immune checkpoint inhibitors (ICIs). 1 Clinical outcomes with PD-(L)1 inhibitors have been positively ...

PURPOSEAxicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little ...

Early-stage, triple-negative breast cancer (TNBC) is the most challenging breast cancer (BC) subtype to treat, characterized by a higher histologic grade, resulting in relatively early and high ...

Targeting CD30 in Diffuse Large B-Cell Lymphoma: Where Does It Fit in? The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...

Background: Patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC) often experience disease relapse even after receiving standard-of-care treatment, e.g. induction chemotherapy ...

The seminal idea of BsAbs dates back to 1961, postulating the creation of an antibody with diverse epitope targeting capabilities that could be produced on a single antibody. 4 It was not until ...

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal ...

PURPOSECurrent approaches to accurately identify immune-related adverse events (irAEs) in large retrospective studies are limited. Large language models (LLMs) offer a potential solution to this ...